| Document |
Document Title |
|
WO/2020/071665A3 |
The present invention relates to an exosome for extending telomeres of cells, a composition comprising same, and a preparation method therefor and, more particularly, to an exosome for extending telomeres of cells, the exosome comprising...
|
|
WO/2020/102721A1 |
The present disclosure provides methods for monitoring inflammation in ALS and other related diseases. Therapeutic interventions based on the results of monitoring methods are also provided.
|
|
WO/2020/102676A1 |
Provided herein are improved methods of manufacturing cells, including T cells and CAR T cells. Also provided herein are methods of manufacturing cells, such as T cells and CAR T cells, obtainable from blood using a method incorporating ...
|
|
WO/2020/102682A1 |
This presently disclosed subject matter relates to an in vitro cell culture comprising a cell monolayer comprising mucus producing cells and a mucus layer, and methods of making and using the same. The methods including culturing mucus p...
|
|
WO/2020/097710A1 |
The present invention describes a method for obtaining freeze-dried tilapia skin, comprising the steps of cleaning by scraping, washing with physiological saline and trimming the edges of the skin; incubating with biocompatible detergent...
|
|
WO/2020/099225A1 |
The invention relates to a culture medium, preferably a cell culture medium, comprising at least one keto acid selected from keto leucine, keto valine, keto isoleucine and keto phenylalanine and/or a salt of these keto acids. The inventi...
|
|
WO/2020/102565A2 |
This disclosure provides, e.g., methods of physically separating sperm carrying a first allele of a phenotype-associated site (e.g., a non-disease allele) from sperm carrying a second allele (e.g., a disease allele). The methods can incl...
|
|
WO/2020/101366A1 |
The present disclosure relates to chimeric polypeptide having TGF-beta activity, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides with improved or novel biological and therapeutic properties.
|
|
WO/2020/098717A1 |
Provided in the present invention is a T-cell receptor (TCR) having the characteristic of binding a FMNKFIYEI-HLA A0201 complex; and the binding affinity of the TCR to the FMNKFIYEI-HLA A0201 complex is at least 5 times that of a wild-ty...
|
|
WO/2020/101037A1 |
Provided is a cell production method comprising: a step of generating a database of peptides specific to cancer cells from a cancer patient, the peptides being identified on the basis of information on the expression of gene products in ...
|
|
WO/2020/100567A1 |
According to the present invention, when cells are cultured using a culture container having fine recessed portions, bubbles collected in the fine recessed portions can be effectively removed, which can be applied to a culture container ...
|
|
WO/2020/101461A1 |
The present invention relates to an organoid and, more specifically, to an organoid and a use thereof, the organoid being produced using a carrier for cell culture which comprises microcapsules containing gelatin, a natural polymer, an o...
|
|
WO/2020/100779A1 |
The purpose of the present invention is to provide a monoclonal antibody, etc., capable of specifically detecting the presence/absence of phosphorylation of MARCKS protein in the brain in the initial stage of onset of a neurodegenerative...
|
|
WO/2020/030979A8 |
The present invention relates to a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or var...
|
|
WO/2020/047527A3 |
The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lym...
|
|
WO/2020/102415A1 |
The present disclosure relates to pluripotent stem cell (e.g., human PSC) based multiplex methods and compositions for identifying genes associated with the pathogenesis of a disorder (e.g., human disorder) and the responsiveness to cert...
|
|
WO/2020/102726A1 |
The present disclosure provides methods for producing TREG and TREG/T1I2 hybrid cells from de-differentiated T cells, said TREG and TREG/T1I2 hybrid cells, populations thereof and compositions thereof. The present disclosure provides met...
|
|
WO/2020/102708A1 |
The present disclosure provides methods for treating cancer. Methods for treating cancer can include administration of pentostatin and cyclophosphamide followed by administration of manufactured T cells. The present disclosure further pr...
|
|
WO/2020/101185A1 |
The present invention relates to: an adipose-derived stem cell sheet containing three-dimensional spherical cells, wherein three-dimensional spherical cells of adipose-derived stem cells are co-cultured on a sheet composed of the adipose...
|
|
WO/2020/100954A1 |
The present invention addresses the problem of providing: an antibody which can bind specifically to CDH6 and has a high internalization activity; an antibody-drug conjugate which contains the antibody and has a high anti-tumor activity;...
|
|
WO/2020/102673A1 |
The present invention relates to the field of purification of algal extracts, methods for their preparation, the unique composition of such purified extracts and their applications. A particular, detailed example of the invention is prov...
|
|
WO/2020/101361A1 |
The present invention pertains to a method for culturing cord blood-derived natural killer cells using transformed T-cells. The method for culturing natural killer cells using transformed T-cells according to the present invention can ef...
|
|
WO/2020/102360A1 |
The present disclosure describes a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a cell product comprising an expanded and enriched population of superactivated cytokine killer T cells, and methods for m...
|
|
WO/2020/101460A1 |
The present invention relates to a carrier for cell culture and, more specifically, to a carrier for cell culture and a cell culture medium composition comprising same, the carrier for cell culture comprising microcapsules which contain ...
|
|
WO/2020/100788A1 |
The main problem addressed by this invention is to provide a novel production method with which it is possible to efficiently directly transform or derive insulin-producing cells from somatic cells. The present invention is a method for ...
|
|
WO/2020/074925A3 |
The invention relates to induced pluripotent stem cells that are generated from cells, for example Adult Stem Cells,that are conditionally-immortalisable. In particular, the invention relates to induced pluripotent stem cells generated f...
|
|
WO/2020/101399A1 |
Provided is a cell culture sheet for a large-capacity incubator. A cell culture sheet according to one embodiment of the present invention is a cell culture sheet provided in a large-capacity incubator having a plurality of sheets dispos...
|
|
WO/2020/099530A1 |
The present invention relates to the use of a quantity of one or more water-soluble calcium salts and a quantity of glass particles for preparing platelet releasate from a sample of a platelet-rich blood composition obtained from a subje...
|
|
WO/2020/086759A3 |
Methods of use and pharmaceutical liquid compositions that are orally administered to the lungs through vaporization and aerosol generating devices providing multifunctional treatment for lung and respiratory diseases are presented.
|
|
WO/2020/101303A1 |
The present invention relates to a peptide comprised of any one amino acid sequence of SEQ ID NOS: 1 to 12 and a use thereof. The peptide of the present invention inhibits the activation of VEGFR-3, upregulates the expression of interfer...
|
|
WO/2020/098672A1 |
Provided is a fusion protein, comprising a first binding domain that specifically binds a tumor-associated antigen, and a second binding domain that specifically binds a CD47 protein, wherein the second binding domain comprises a mutant ...
|
|
WO/2020/100481A1 |
A method for producing brain organoids comprising a step of culturing a neuroectoderm marker-positive cell aggregate in a culture medium that contains extracellular matrix at a concentration of more than 10 volume%.
|
|
WO/2020/102701A1 |
The present disclosure provides methods for the production of manufactured T cells, manufactured T cells obtained by said methods and compositions comprising said manufactured T cells. Such T cells demonstrate an improvement over previou...
|
|
WO/2020/099384A1 |
The invention relates to a method for the in vitro generation of antigen-specific antibodies or cells producing thereof, said method comprising culturing B cells with an antigen-coated carrier for at least 3 days, wherein said antigen-co...
|
|
WO/2020/102715A1 |
The present disclosure provides methods for producing de-differentiated T cells, said de- differentiated T cells, populations thereof and compositions thereof.
|
|
WO/2020/055932A3 |
Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided. Also provided are methods for GM-...
|
|
WO/2020/102062A1 |
A cell culture cartridge is provided comprising a plurality of zones geometrically configured to provide for symmetrical fluid flow with each of the plurality of zones to avoid dead areas in flow within each of the plurality of zones. In...
|
|
WO/2020/102731A1 |
The present disclosure provides methods for treating ALS using pentostatin and cyclophosphamide treatment followed by TREG and/or TREG/Th2 hybrid cells from dedifferentiated T cells. The present disclosure further provides methods for pr...
|
|
WO/2020/100789A1 |
The main problems addressed by this invention are the provision of: a method for producing insulin-producing cells from somatic cells without artificial gene transfer; insulin-producing cells obtained using said production method; and a ...
|
|
WO/2020/099674A2 |
The present invention provides: a novel method for the production of truly fully human monoclonal antibodies against specific antigens of our choice using isolated human blood cells. These antigens may include but are not limited to pept...
|
|
WO/2020/099572A1 |
The present invention provides polynucleotides and viral vectors for transfection of a mammalian host cell, preferably lentiviral vectors, encoding at least one CAR (chimeric antigen receptors)and a promoter from the Wiskott-Aldrich synd...
|
|
WO/2020/101571A1 |
The present invention relates to a method of inducing mesenchymal-epithelial transition (MET) in a basal-like (or mesenchymal-like) cancer cell by contacting the cancer cell with an inducer of mesenchymal-epithelial transition for a time...
|
|
WO/2020/101327A1 |
The present invention relates to microcapsules containing natural oil and, more specifically, to microcapsules which contain gelatin, natural polymers, oil, and an oil thickener and have enhanced mechanical properties, and a preparation ...
|
|
WO/2020/097026A1 |
The present disclosure describes novel methods for preparing leaf-derived plant cell suspension cultures. The cell suspension cultures produced by the methods provide a renewable and efficient source of protoplasts for high-throughput tr...
|
|
WO/2020/095230A1 |
Disclosed herein are pharmaceutical compositions and methods comprising or utilizing placental adherent stromal cells. The pharmaceutical compositions may be indicated for ameliorating or treating various disorders, e.g., impaired glucos...
|
|
WO/2020/096899A1 |
The disclosure provides for compounds comprising cancer specific marrow infiltrating lymphocytes and methods for making and using the same.
|
|
WO/2020/096339A1 |
The present invention relates to a biomarker for predicting the ability of mesenchymal stem cells to proliferate and migrate and uses thereof, more particularly to a biomarker comprising peroxiredoxin 6 for predicting the ability of mese...
|
|
WO/2020/069000A9 |
The present invention includes a method for screening one or more agents that modulate Regulatory T cell (Treg) activity, the method comprising the steps of: incubating a population CD4+ cells isolated from human blood peripheral mononuc...
|
|
WO/2020/095921A1 |
The purpose of the present invention is to provide a novel peptide. This peptide contains the amino acid sequence represented by sequence number 61, and inhibits protease.
|
|
WO/2020/097403A1 |
The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog ...
|
